Clinical Trials & Pipeline
Mirna is a biopharmaceutical company focused on microRNA-based oncology therapeutics.
LEARN MORE ABOUT US
MRX34, Mirna’s first product candidate, was the first microRNA mimic to enter clinical testing.
November 10, 2016
Mirna Therapeutics Reports Third Quarter 2016 Financial Results and MRX34 Clinical Program Updates
September 20, 2016
Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34
VIEW ALL NEWS
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.